Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region - Forecast (2016-2021)
|出版日||ページ情報||英文 136 Pages
|全身性エリテマトーデス市場：治療（抗マラリア薬、非ステロイド抗炎症性薬、コルチコステロイド細胞毒性免疫抑制薬、生物製剤、小分子）、地域別の予測 Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region - Forecast (2016-2021)|
|出版日: 2016年09月22日||ページ情報: 英文 136 Pages||
Systemic lupus erythematosus, also commonly known as lupus, is an autoimmune disease which results in inflammation of tissues in the body with common symptoms like fever, fatigue, skin rashes, malaise, joint pain, and temporary loss of cognitive ability. Immune response is directed toward the body's own cells, resulting in acute or chronic inflammation. Symptoms of lupus are general and hence often mistaken with symptoms of other diseases. This results in unnoticed progression of disease in the body. The disease is more common in women and usually affects individuals in the age group of 25 to 45. Although the main cause of disease is unknown, it is linked to genetic and hormonal factors. Globally increasing awareness about lupus is expected to remain key growth driver during the period of study.
Geographically, North America dominates the systemic lupus erythematosus market driven by best in class infrastructure, easy access to healthcare, higher awareness about the disease amongst citizens as well as practitioners, and higher spending by the citizens towards healthcare expenditure. North America was followed by Europe and Asia-Pacific as second and third largest markets for systemic lupus erythematosus market. Asia Pacific is projected to have fastest growth, owing to rapidly developing medical infrastructure, increasing medical tourism, increased spending, and increasing awareness amongst population in developing nations such as China, and India in this region.
This report identifies the global systemic lupus erythematosus market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to the systemic lupus erythematosus market.
Systemic Lupus Erythematosus Market research report is classified on the basis of therapies. Some of the major therapies covered in this report are as follows: Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules
This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
F. Hoffmann-la roche ltd
Glaxosmithkline plc (gsk)
Hadasit medical research services and development
Hansa medical ab
More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"